Agilent “Dialogues in CDx” Podcast Series

Episode 7: PD-L1 Testing in Head & Neck Cancer - Current Practice and Clinical Impact

In Episode 7 of Agilent’s Dialogues in CDx, we turn our focus to recent advances in head and neck cancers, a field marked by rapid evolution in diagnostics and clinical decision‑making. To unpack what’s changing and why it matters for patient care, we welcome two specialists at the forefront of this space, offering complementary insights from pathology and oncology. Professor Cécile Badoual is a pathologist and Head of the Department of Medical Biology and Pathology at Gustave Roussy in Paris. An expert in head and neck cancers, her research focuses on the tumor microenvironment of HPV‑associated cancers. Beyond her current roles, she has held numerous senior academic and institutional leadership positions, and her career has been recognized with several prestigious honors for her contributions to pathology and translational cancer research. Our second guest, Dr. Marc Oliva, is a medical oncologist and clinician‑scientist with a focus on head and neck malignancies and early drug development. He trained at Princess Margaret Cancer Centre in Toronto and is currently a full consultant at the Catalan Institute of Oncology in Barcelona.  Dr. Marc Oliva has an established record of peer‑reviewed scientific publications and is actively engaged in the scientific publishing process as an editor and regular reviewer for leading international oncology and immunology journals. This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay. For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's ⁠⁠⁠⁠⁠CDx Digital Education Portal⁠⁠⁠⁠⁠ [https://bit.ly/3YTTOOk] today. D0147437_1.00

Episode 6: PD-L1 Prevalence - Reconciling clinical data with real world data

In episode number 6 of Agilent’s “Dialogues in CDx” podcast, we explore how to bridge the gap between clinical data and the realities of daily laboratory practice. To unpack this topic, we are joined by two distinguished experts who bring complementary perspectives from pathology and oncology. Dr. Birgit Guldhammer Skov, consultant pathologist at the Department of Pathology, Sjaelland University Hospital in Denmark, works primarily with lung cancer. She has been involved in evaluating PD-L1 in lung cancer since the biomarker was introduced in 2016. Our second guest, Professor Inge Marie Svane, is a consultant oncologist at the Department of Oncology at Herlev Hospital in Denmark and Director of the national “Center for Cancer Immune Therapy” (CCIT). She currently leads oncology care for melanoma patients in eastern Denmark and has a special interest in real-world data and new treatment strategies for anti-PD1 refractory patients. This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay. For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's ⁠⁠⁠⁠CDx Digital Education Portal⁠⁠⁠⁠ [https://bit.ly/3YTTOOk] today. D0133061 _1.00

Episode 5: Interpretation of CDx markers - How do we ensure proper training?

In the fifth episode of Agilent’s “Dialogues in CDx” podcast, we discuss how to ensure proper training for PD-L1 interpretation. Two leaders who are shaping this space discuss why training is important, the best practices, and how it impacts patient care.  The first guest in this episode is Dr. Bharat Jasani, Emeritus Professor in Cancer Pathology in the School of Medicine at Cardiff University. Dr. Jasani has been extensively involved in training of more than 1,000 pathologists worldwide in quality assurance and scoring, as well as interpretation of cancer biomarker expression, particularly PD-L1 and HER2.   Also joining the conversation is Karin Salomon who has worked for Agilent Technologies in R&D for more than 20 years as a principal microscopy expert. Karin is evaluating thousands of HER2 and PD-L1 stained slides every year and trains pathologists in scoring of various biomarkers through Agilent’s Biomarker Pathologist Training Program in Europe.  This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay. For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's ⁠⁠⁠CDx Digital Education Portal⁠⁠⁠ [https://bit.ly/3YTTOOk] today.   D0133059 _1.00

Episode 4: Tissue issues - Overcoming sample limitations for PD-L1 testing

In the fourth episode of the “Dialogues in CDx” podcast series, we explore the issue of sample limitations and how pathologists can address them when performing PD-L1 testing. Two leaders in gastrointestinal pathology join the host Scott W. Boyer in an engaging discussion of the main challenges and solution strategies.  Dr. Mar Iglesias Coma is Head of the Pathology Department at Hospital del Mar in Barcelona and specializes in gastrointestinal pathology. Since 2008, Dr. Iglesias has served as an associate professor at the Faculty of Medicine in Pathology, and is a contributor to multiple innovation projects, particularly within the fields of digital pathology, tools for multidisciplinary tumor committees, biomarkers, and laboratory applications.   Also joining the conversation is Professor Manuel Rodriguez-Justo, a consultant in gastrointestinal pathology and haematopathology at University College London Hospitals as well as a Professor of Onco-Pathology at UCL-Cancer Institute.  Professor Rodriguez-Justo has implemented molecular pathways and biomarker testing in gastrointestinal cancers and is involved in designing and developing multiple national and multicenter trials.   This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay. For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's ⁠⁠CDx Digital Education Portal⁠⁠ [https://bit.ly/3YTTOOk] today. D0131924 _1.00

Episode 3: The Pathologist-Oncologist Connection - Optimal Reporting of the PD-L1 Results

In this third episode of the "Dialogues in CDx" podcast series, you’ll listen to the distinguished guests Dr. Phillippe Taniere and Dr. Shobhit Baijal once more. The previous episode dissected the PD-L1 testing journey from biopsy to report. This episode will focus on the topic of PD-L1 reporting: What information should the pathologist provide for the oncologist? What information helps the oncologist make the best treatment decisions? As in the second episode, perspectives from both a pathologist and an oncologist are presented. Dr. Phillipe Taniere is a Consultant Histopathologist and Clinical Service Lead for Molecular Pathology at University Hospitals Birmingham in UK. Dr. Taniere’s department completed 20,000 CDx tests last year. Also joining the discussion is Dr. Shobhit Baijal, a Consultant Medical Oncologist at the University Hospitals Birmingham NHS Trust and an Honorary Associate Professor at the University of Birmingham, where he specializes in the treatment of thoracic and colorectal malignancies. Dr. Baijal specializes in all forms of cancer therapy and is a UK Chief and Principal Investigator for National and International studies. He is also a steering committee member of the British Thoracic Oncology Group. His vast experience provides invaluable input to the discussion. This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay. For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's ⁠CDx Digital Education Portal⁠ [https://bit.ly/3YTTOOk] today.   D0130749_1.00